Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 20;15(12):e50817.
doi: 10.7759/cureus.50817. eCollection 2023 Dec.

Characteristics of Eyes With Neovascular Age-Related Macular Degeneration Requiring Frequent Anti-vascular Endothelial Growth Factor Injections

Affiliations

Characteristics of Eyes With Neovascular Age-Related Macular Degeneration Requiring Frequent Anti-vascular Endothelial Growth Factor Injections

Michiko Taketani et al. Cureus. .

Abstract

Objective In this study, we aimed to determine the characteristics of neovascular age-related macular degeneration (AMD) patients requiring frequent anti-vascular endothelial growth factor (VEGF) therapy. Methods This was a retrospective observational study involving the review of 32 eyes of 31 patients (25 men and six women, mean age: 74.3 years) treated with anti-VEGF injections for less than eight weeks and at least one year of follow-up. The subtype of macular neovascularization (MNV), follow-up duration, number of injections, visual acuity, and exudative changes during the study period were evaluated. Results Twenty-nine eyes (90.6%) had MNV under the retinal pigment epithelium (RPE), including 11 eyes with type 1 MNV and 18 eyes with polypoidal choroidal vasculopathy (PCV). Only three eyes had type 2 MNV (9.4%) above the RPE. The mean follow-up period was 28.7 ± 16.5 months, and the mean number of injections was 21.5 ± 11.8. The mean visual acuity [logarithm of the minimum angle of resolution (logMAR) units] was 0.19 ± 0.23 at the initial visit to our hospital, which decreased non-significantly to 0.24 ± 0.4 at the final visit (p=0.63). The exudation in four eyes (two with type 1 MNV and two with PCV) never resolved. The exudation remained in 27 eyes (84%) even after every four weeks of treatment, and it was present in five eyes (16%) in the treatment interval of eight weeks. Conclusions In the eyes receiving frequent anti-VEGF injections, the sub-RPE MNV might have affected the response to the treatment. Although patients requiring frequent anti-VEGF therapy did not have a significant decrease in their visual acuity, 84% of the eyes had exudations even with monthly injections.

Keywords: dry macula; neovascular age-related macular degeneration; non-responders; polypoidal choroidal vasculopathy; tachyphylaxis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared financial relationships, which are detailed in the next section.

Figures

Figure 1
Figure 1. Tachyphylaxis case worsens after two-month interval of injection
The patient was an 81-year-old man. Optical coherence tomographic (OCT) images in eyes require frequent anti-vascular endothelial growth factor treatment during the follow-up period a: At the baseline. b: Dry macula at three months. c: Wet macula at 24 months. d: Wet macula at 26 months. White arrows indicate the presence of subretinal fluid

Similar articles

References

    1. Ranibizumab for neovascular age-related macular degeneration. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. N Engl J Med. 2006;355:1419–1431. - PubMed
    1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, et al. N Engl J Med. 2006;355:1432–1444. - PubMed
    1. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. N Engl J Med. 2011;364:1897–1908. - PMC - PubMed
    1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Heier JS, Brown DM, Chong V, et al. Ophthalmology. 2012;119:2537–2548. - PubMed
    1. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE, Lalwani GA, Rosenfeld PJ, et al. Am J Ophthalmol. 2007;143:566–583. - PubMed

LinkOut - more resources